MammoScreen breast cancer screening AI

Organization
Therapixel · France
Solution Type
Ready Product / Solution
Collaboration
Business Collaboration (Joint Venture), Licensing

1. Technology overview

Therapixel is a French medical imaging AI company set up in 2013 by Olivier Clatz and Pierre Fillard, with headquarters at 455 Promenade des Anglais in Nice and research teams in Paris. It refocused entirely on radiology after selling its surgical products unit in June 2020.

Its product MammoScreen is an AI tool for interpreting screening mammograms and enables breast cancer detection at first reading. It is FDA cleared, including 3D mammography (digital breast tomosynthesis), and CE marked. The company won the DREAM Digital Mammography Challenge in 2017 and its investors include Creazur, Omnes and M Capital.

2. Highlighted features & specifications

  • MammoScreen 2D/3D: AI interpretation of digital mammography and tomosynthesis.
  • First-reading detection: flags suspicious findings at the initial read.
  • Prior exam comparison: a version that leverages prior exams for better accuracy.
  • FDA 510(k) clearance for 3D mammography, granted in November 2021.
  • Partner deployment: offered through provider networks such as Onsite Women's Health.
  • Clinical evidence: prospective French study on AI as second reading in screening.

3. Potential application

Private hospital groups in Vietnam could use MammoScreen as a second reader for screening mammograms. Women's health clinics could prioritize suspicious cases for radiologist review. Breast imaging centers could use it for quality control audits.

4. Benefits

Supports radiologists with AI-assisted reading of 2D and 3D mammograms.

The company reports detection of 42% of cancers one year before diagnosis and 38.5% two years before, as company-reported figures.

FDA cleared and CE marked, easing deployment in the US and Europe.

Used at large providers, including Mayo Clinic and the Onsite Women's Health network of 150+ locations (per Therapixel news).

6. Other information

Founded 2013; headquarters at 455 Promenade des Anglais, 06200 Nice, France. Investors include Creazur, IT Translation, Omnes, M Capital and Region Sud Investissement. Mayo Clinic selection dated June 2025 and Onsite Women's Health partnership April 2025.

Not ready to connect yet?

Save this solution and come back when you are ready to talk to the provider

Trusted by Our Partners

TechFest VietnamIOM – UN MigrationGIZ (Deutsche Gesellschaft für Internationale Zusammenarbeit)APED – Cục Phát triển doanh nghiệp tư nhân và kinh tế tập thểSIHUB – Startup and Innovation Hub of Ho Chi Minh CityHợp tác Đức (Deutsche Zusammenarbeit)SCE & Investment PromotionStartup Vietnam Foundation (SVF)National Startup Support Center (NSSC)01BoosterQuest VenturesBộ Tài chính (Ministry of Finance)ITPC – HCMC Investment and Trade Promotion CentreJICA – Japan International Cooperation AgencyNational Innovation Center (NIC)UK GovernmentBCG – Boston Consulting GroupHAWEEHeineken VietnamTalentnetMB BankVIREA – Liên chi hội Bất động sản Công nghiệp Việt NamJobTestGlobal Supply Chain Support Fund / Aavishkaar CapitalKDANPSE / JPS – Phúc Sang MinhG-AsiaPacificBlueScopeLPBankUlsan Center for Creative Economy & InnovationĐại học Bách khoa Hà Nội – Trường Điện - Điện tửVINK – Vietnam Innovation Network in KoreaTencent WeStart (Shenzhen)Ulsan CollegeK-StartupFaslinkShinhan Future's LabShinhan SecuritiesShinhan FinanceShinhan BankShinhan Life

Start with the right connection

We make innovation easy to access for every business everywhere. The next deal is you.

Contact Us